Angelo Kourkafas | Source | Senior Strategist, Investment Strategy at Edward Jones
Angelo Kourkafas
Angelo is responsible for analyzing market conditions, assessing economic trends and developing portfolio strategies and recommendations that help investors work toward their long-term financial goals. Prior to Edward Jones, Angelo worked in New York as an equity trader and held roles at HSBC and Ameriprise Financial.
-
Edward Jones (https://www.edwardjones.com/)
Investment Strategy Analyst -
Edward Jones (https://www.edwardjones.com)
Senior Strategist, Investment Strategy
-
Strategists lower their sights for Canada's TSX after COVID-19 shock: Reuters poll
Canada's main stock index is set to extend its rebound over the coming months as well as in 2021, but will fall short of previous expectations as the global economy struggles to fully recover from the coronavirus crisis, a Reuters poll found.
Article -
Dow climbs 480 points, Nasdaq snaps five-day losing streak as stocks rebound to start October
The market rebounded on the first day of October after a tumultuous September.
Article -
CANADA STOCKS-TSX falls for second day as 'growth scare' evolves
Canada's main stock index on Wednesday extended its pull back from a record high, with resource shares among the declining stocks as investors grew more worried about prospects for the global economy.
Article
-
No bull market is completely devoid of setbacks. Even the second-longest bull market on record (2009–2020) had its share of blemishes. During that period, there were six 10% corrections driven by a variety of factors, including growth scares, trade wars, oil prices and shifts in Fed policy.
-
A mid-cycle slowdown, or growth scare appears to be developing. Growth estimates are being revised lower at the same time as expectations and valuations are elevated.
-
We have seen this rotation back to the so-called reopening plays and the more cyclical areas, which I think makes a lot of sense over the next couple of weeks as we think about the Covid trends improving, with the cases falling from last month’s peak, and the news about the Merck pill appears promising.
